If you’re taking CBD too, perhaps you’ve also googled: Can you take too much CBD? In order for CBD to be toxic to your system, you would have to ingest almost 20,000 mg of CBD oil in a very short amount of time, according to a 2011 study published in the journal Current Drug Safety. But that doesn’t mean you can take gummy after gummy just because they taste like candy.
With the 2018 Hemp Act, part of the 2018 Farm Bill, signed Dec. 20, 2018, all products derived from industrially farmed hemp grown in the U.S. are now legal in all 50 states, ending a more than an 80-year ban of large-scale hemp farming in this country. This means that this year is really where CBD is going to hit the mainstream, as Well+Good’s 2019 wellness forecast suggested. This *also* means it will be a lot easier for researchers to test CBD and its effects, which was previously difficult because of federal regulations around hemp. Hence why scientists aren’t yet 100 percent conclusive on CBD’s effects — and why it’s important to educate yourself before getting started.
Because CBD oils are not currently regulated by the FDA, choosing the right one can be daunting, and sometimes a little bit sketchy. Luckily, you can head over to the website CBD Oil Review to research different brands. It’s also important to note that just because it’s unlikely you can take enough CBD oil to endanger your health, taking too much CBD could make you feel bajiggity. Also, studies have found that CBD oil is known to interact with certain medications, so make sure to consult your doctor or pharmacist if you’re currently taking any prescriptions.
Full story at Bustle
Waterloo Region’s city and township councils must decide soon if they’re opting in or out when it comes to having cannabis stores.
The landscape is uncertain, and the stakes are high.
Many local councils will decide at their first meeting in January, the week of the 14th. But that will be after the first wave of store approvals.
It has been legal since Oct. 17 to purchase marijuana online from the Ontario Cannabis Store.
When it comes to physical stores set up in communities, however, most municipalities are still on the fence.
Municipalities that say yes to physical cannabis stores can’t change their minds later and opt out. They’ll be in for good.
Municipalities that say no can change their minds later. But if they wait, they’ll miss out on extra funding to help pay for extra police and bylaw enforcement officers.
One problem of agreeing to the stores is that local officials don’t have any say in the location, as long as it’s suitable for a retail outlet.
The stores can’t be within 150 meters of a school. But other than that, the city or township has no ability to require, for example, that stores stay a certain distance away from one another.
The North American experience with alcohol can offer some lessons now. When alcohol was illegal, it was easy for children to buy it because once you got to the point of sale, there were very few rules. And also, the illegal booze could make you sick, because its manufacture wasn’t regulated.
Read the full article at The Record
The hemp industry still has work ahead to win legal status for hemp-derived cannabidiol, or CBD oil, as an ingredient in food or dietary supplements despite the big farm bill President Donald Trump signed last week designating hemp as an agricultural crop.
CBD oils have become increasingly popular in lotions, tinctures, and foods, but their legal status has been murky and the Food and Drug Administration has sent warning letters to some companies making health claims for CBD.
In a statement following Thursday’s bill signing in Washington, FDA Commissioner Scott Gottlieb restated his agency’s stance that CBD is a drug ingredient and therefore illegal to add to food or health products without approval from his agency.
An FDA-approved drug for the treatment of seizures, Epidiolex, contains cannabis-derived CBD. GW Pharmaceuticals’ syrup became the first prescription drug derived from the cannabis plant in June.
The FDA statement also specified parts of hemp that are safe as food ingredients, but the CBD stance disappointed advocates. Courtney Moran, a lobbyist for Oregon hemp farmers, said she plans to work with U.S. Sen. Ron Wyden, an Oregon Democrat, to nudge the FDA toward greater acceptance of CBD.
Read more on Chicago Tribune
The popularity of cannabis oil vaporizer cartridges, otherwise known as “tanks” among cannabis users, is exploding at a rate faster than any other product on dispensary shelves.
According to data submitted by Colorado’s recreational cannabis industry, cannabis vaporizer cartridge sales increased by 400 percent in 2016 alone. If you’ve been a medical cannabis patient here in Massachusetts before the first recreational shops opening Nov. 20, you’ve witnessed shortages in this hot commodity.
Cannabis vaporizer cartridges are small tanks, typically made of glass or plastic, and pre-filled with a cannabis concentrate. Similar to traditional e-cigarettes, the cannabis cartridge screws into a rechargeable battery containing a button which atomizes, or activates, the vapor almost immediately once pressed.
The three most-common cannabis extracts you will find in cartridge form are those derived from distillation, CO2 extraction or live resin extraction. They will often be split up this way on the product menu. But it’s still unclear to many novices what these things mean, so here’s a brief breakdown of each.
The distillate is clear, highly refined oil which can be made from any cannabis extract, regardless of quality. The heat strips away most of the cannabinoids and the terpenes, often leaving only THC and CBD behind.
The most-popular cannabis vaporizer cartridges by far, are those made with oil collected from CO2 extraction. CO2 extracts are the most compatible with vaporizer cartridges because they do not require additives of any kind to meet the viscosity needed to function in the battery atomizers made for them.
Continue Reading at Metro West Daily News
MedReleaf Corp. and CanniMed by Aurora received Health Canada approval to sell cannabis oil soft-gel capsules, and CannTrust Holdings Inc. announced a range of new cannabis oil, vegan-based, hard-shell capsules—Tilray had introduced the product in Canada last year.
One of the main benefits of capsules is that they include a pre-measured dose and are a viable option for cannabis consumers who are opposed to using syringes to measure their dose.
“Based on third-party research conducted by Cannabis Evidence, an online resource in the field of medical cannabis research, three in four patients out of 709 screened preferred alternative formulations to smoking cannabis. The majority of these patients prefer a capsule/tablet over other oral dosage forms like oils,” reports Kaivan Talachian, Pharm.D., and R.Ph, vice-president of professional services at CannTrust.
While capsules help ensure correct dosages, the complications of determining the appropriate dose for cannabis don’t end there. “Cannabis tends to impact people in different ways, and can’t be prescribed in the same way as traditional medicine. There is a need for continuous dialogue between patients and doctors to ensure that their cannabis therapy is working as intended,” cautions Dr. Mahabir.
Cannabis capsules offer a straightforward way to know precisely how much an individual has consumed, and can potentially be a healthier alternative to smoking cannabis and inhaling harmful carcinogens.
Read more at Growth Op
Since last Thursday, medical cannabis has been legal in the UK. This means specialist doctors are now able to prescribe cannabis products for conditions where there is a proven medical benefit, potentially helping thousands of people suffering from severe forms of epilepsy, multiple sclerosis (MS), chronic pain, and nausea as a result of chemotherapy, among other ailments.
This landmark change in the law occurred after several stories came to light of sick children suffering under prohibition, including Billy Caldwell. The severely epileptic 12-year-old hit headlines earlier this year when the Home Office confiscated the Canadian-bought cannabis oil that made his condition manageable. Nationwide horror at the situation prompted Home Secretary Sajid Javid to order a review of the law, after which it was decided that cannabis should be changed from a Schedule 1 drug (no medical value) to a Schedule 2 (can be prescribed).
An MS Society statement said: “It’s likely that nothing will change in the short-term for the one in ten people who get relief from pain and muscle spasms by using medical cannabis. We’re calling for the interim guidance of prescribing medical cannabis to be urgently reviewed so that access to the treatment isn’t so restricted.”
Despite the limited scope laid out in the guidelines, Health Secretary Matt Hancock seemed to imply that doctors are being given a certain level of flexibility. He said: “Doctors need to use their clinical judgment, and having guidance in place helps. Ultimately, the need to treat a person and the responsibility for that falls on the shoulders of a doctor—that’s what they do.” Indeed, there will be no direct policy from a government that limits the conditions for which medical cannabis can be prescribed.
Read the full article at Vice
In the wake of cannabis legalization in Canada, a team of scientists has delivered encouraging news for chronic pain sufferers by pinpointing the effective dose of marijuana plant extract cannabidiol for safe pain relief without the typical “high” or euphoria that THC produces. The findings of their study have been published in the journal PAIN.
Cannabis indica and sativa are the two main cannabis strains that produce the pharmacological principles known as tetrahydrocannabinol (THC) and cannabidiol (CBD). The team demonstrated that CBD does not act on the CB1 cannabinoid receptors like THC, but through the mechanism that binds specific receptors involved in anxiety (serotonin 5-HT1A) and pain (vanilloid TRPV1).
“In animal models of neuropathic or chronic pain, we found that low doses of CBD administered for seven days alleviate both pain and anxiety, two symptoms often associated,” says the study’s first author Danilo De Gregorio, a postdoctoral fellow at McGill University.
Lead author Gabriella Gobbi sees this as a new advancement for the evidence-based application of cannabis in medicine with CBD likely offering a safe alternative to THC and opioids for chronic pain, such as back pain, sciatica, diabetic, cancer, or post-trauma pain.
“Our findings elucidate the mechanism of action of CBD and show that it can be used as medicine without the dangerous side effects of the THC,” says Gobbi, a professor of psychiatry.
Despite widespread public usage, little clinical studies exist on CBD, which became legal in Canada on October 17, 2018, following the passage of Canada’s Cannabis Act.
According to a new study, cannabis oil can “significantly” improve Crohn’s disease symptoms.
“(S)tudies have shown that many people with Crohn’s disease use cannabis regularly to relieve their symptoms,” Dr. Timna Naftali, an Israeli gastroenterologist who also teaches at Tel Aviv University, said in a written statement. “It has always been thought that this improvement was related to a reduction in inflammation in the gut and the aim of this study was to investigate this.”
Crohn’s disease is a lifelong inflammatory bowel disease (IBD) that can cause severe belly pain and chronic diarrhea.
Dr. Naftali, whose study is being billed as the first of its kind, found that an eight-week treatment with cannabis oil containing a four to one CBD to THC ratio produced clinical remission in up to 65 percent of individuals with Crohn’s disease. The randomized, placebo-controlled study involved 50 people with moderately severe forms of the disease. The group that received cannabis oil also reported significant improvements in their quality of life.
Read more at CTV News
It is a safe bet that anyone traveling to Jamaica on vacation is open to the experience of, if not directly looking for, an opportunity to legally consume cannabis. Cannabis tourism in Jamaica is taking off, as properties across the Caribbean island are highlighted for their ingenuity in the fast-growing industry. Coral Cove is the perfect example of one such retreat.
Originators of the cannabis tourism experience, Higher Way Travel carved out a niche by bringing cannabis tourists to Hawaii for the Cannabis Expo in 2017 and ensuing festivities. Run by April Black, wife of infamous pot personality Bobby Black, Higher Way Tours have since branched out into facilitating tourist experiences in Jamaica.
Coral Cove is off the proverbial beaten path. There are some unpaved roads and potholes on the way there, but the remoteness and seclusion of the location make it the antithesis of a tourist trap. The resort is named after the abundance of coral that is artfully incorporated into the masonry work on the property.
The retreat resides far away from prying eyes. People who want to walk around without winding up on social media or be gawked at by other guests will especially appreciate this homey hamlet, with its private, secluded waterfront cove. Although, the cove itself is heaven on Earth for aspiring influencers who are eager to snap selfies in exotic locales.
Continue Reading at Forbes
Coca-Cola is looking at pitching cans of cannabis-infused wellness drinks to consumers in the latest bid by a big beverage behemoth to tackle the budding market for potentially potent enhanced potables.
“Along with many others in the beverage industry, we are closely watching the growth of non-psychoactive CBD as an ingredient in functional wellness beverages around the world,” the company said in a statement issued in response to a report from the Canadian BNN Bloomberg new service.
BNN reported that Coca-Cola was in talks with cannabis producer Aurora Cannabis to make marijuana-infused wellness drinks. Aurora Cannabis did not confirm that it was in talks with Coke, but the company’s chief executive did acknowledge that it had been in conversation with several beverage makers over the last few months.
Drinks infused with either cannabinoid-like CBD, which has medicinal, pain-relieving qualities, and THC, which gets users high, have become popular in states in the U.S. where the drug is legalized and in Canada where it has been fully decriminalized nationally.
The experiments in better sales through new chemistry come at a time when demand for both beer and bubbly sodas is slowing. Beer is being supplanted by booze and wine among American consumers (or a rising number of teetotalers are eating into sales of both). Meanwhile, sugary drinks also have seen their popularity dwindle as new consumers reach for the kombucha rather than the Coke.
Continue Reading at TechCrunch
Under Ohio’s new medical marijuana law, which goes into effect on September 8, the Board’s clarification on CBD oil, which can derive from either marijuana or hemp, is illegal. The board says CBD oil must go through the same rigorous testing procedures and comply with the same rules as real cannabis.
CBD is not legal in all 50 states. According to the Agricultural Act of 2014 (AKA the farm bill), only CBD cultivated under state law “in which such institution of higher education or state department of agriculture is located, and such research occurs,” is legal. CBD that is not manufactured from hemp grown under a state pilot program or for academic research is not legal.
Additionally, according to Jo Ingles of WOSU public radio Ohio, “The board adds the only legal way to sell CBD is through a medical marijuana control program dispensary. The Ohio Department of Commerce approved 56 dispensary licenses, five of which are in Franklin County.”
Full article at Forbes
A public hearing will be held next month to take comments on a moratorium halting new cannabis operations in Columbia County.
Commissioners last month enacted the moratorium on applications for production, processing or retail operations. The moratorium did not affect the one retail cannabis store in the county or an indoor grow operation approved by the county hearing examiner before the moratorium was enacted.
The resolution for the moratorium stated the current county code governing recreational and medical cannabis operations “allows for too much public safety issues and concerns, disallows for appropriate moderation and is in need of complete revision to ensure only suitable development occurs.”
If your pup has long suffered from anxiety, you’ve probably tried every treatment option in the book — which might have left you wondering as an alternative, “Is CBD OK for dogs?” There’s evidence that cannabinoid oil, which is derived from the cannabis plant but has no THC in it, can help humans with everything from anxiety to pain management — so why not dogs?
According to PetMD, cannabis oil can treat a wide range of health conditions in dogs, including not just anxiety and stress, but also seizures, nausea, arthritis, back pain, and gastrointestinal issues. (Indeed, the FDA recently approved a CBD-based medication for the treatment of epilepsy in humans, so it’s not too far of a stretch to examine CBD oil as a treatment for seizures in dogs, too.) And yes, it’s safe for your pup; in fact, it even has a leg up on some traditional pet medications in that, when properly dosed, it doesn’t have any life-threatening side effects.
According to Mashable, BarkShop began offering health and wellness supplements for dogs in 2017 and started work developing dog-specific CBD supplements in January of 2018. They’re available in both treat form and straight extract; the treats can obviously be eaten as is (think of them as CBD gummies for pets), while the extracts can be mixed with food.
Research tested and sourced from “family farms in Colorado,” the supplements claim to be useful for everything from anxiety brought on by thunderstorms or car rides to relieving nausea and treating seizures.
Read more at Bustle
Another cannabis stock is gearing up to trade publicly on the Canadian Stock Exchange (CSE). Tree of Knowledge Inc. (TOK) is the latest company to apply for a listing application on the market, following a growing list that includes headline-making companies such as MedMen (CNSX:MMEN) and The Green Organic Dutchman (TSX:TGOD.
A group of business and medical professionals founded TOK in 2015 with the goal of building a trusted CBD product line. The company also has an advisory board with leaders from diverse sectors from medicine to professional sports. Since then, the company has expanded to three continents and has grown its brand of CBD products called EVRCBD—oils, capsules, tinctures and vape pens.
Courtland Capital and TOK announced their merger agreement in April. Courtland is in the process of forming a Nevada subsidiary company to merge with TOK, whereby TOK shareholders will receive Courtland common shares, owning approximately 88 percent of the outstanding undiluted Courtland shares. The company plans to delist from the TSX Venture Exchange and instead pursue the listing on the CSE. Courtland will change its name to TOK in the reverse merger.
TOK Chairman Michael Caridi explained that TOK and Courtland make a great partnership moving forward in their quest to becoming a medical cannabis industry leader. Caridi cites the sheer magnitude of the medical cannabis market, and looks forward to the “ability to mature and expand [their] reach into the markets [they] are in and plan on entering.”
Like many other fitness-minded young professionals, a 25-year-old Boston resident named Cameron adheres to a fairly typical pre-workout routine. There’s the 20 minutes of stretching, generally followed by some light cardio.
As marijuana legalization has pushed the drug further toward the mainstream — and a longstanding social stigma has begun to dissipate — more individuals are taking up before hitting the weight room, sports field, or mixed martial arts mat.
While the idea might seem inherently counterintuitive — weed, after all, is a substance more commonly paired with Doritos than deadlifts — there is a passionate contingent that swears by it.
“It’s a weird phenomenon, but it’s an increasingly common phenomenon,” says Peter Grinspoon, a primary care doctor at Massachusetts General Hospital and author of the book “Free Refills: A Doctor Confronts His Addiction.” “The fact that a lot of people are saying it helps them can’t be ignored.”
Research into marijuana’s benefits has been notoriously scant, due in large part to the drug’s federal classification as a Schedule 1 substance — meaning that, along with heroin, LSD, and ecstasy, it’s deemed to have “no currently accepted medical use and a high potential for abuse.” And the few studies that do exist offer relatively little insight into the drug’s effects during physical activity, beneficial or detrimental.
Read the full article at Boston Globe
Doctors have been warned against rushing to prescribe medical cannabis despite Australians’ acceptance of its use.
To date, the evidence on the effectiveness of medical cannabis remains “limited”, said Jennifer Martin and Associate Professor Yvonne Bonomo in an editorial for the Royal Australasian College of Physicians (RACP).
Published in the Medical Journal of Australia, the editorial says the usual regulatory processes designed to protect patients from potential serious harms caused by medicinal cannabinoids must be adhered to.
In Australia, medicinal cannabis is legal but patient access is still very difficult.
The Therapeutic Goods Administration (TGA) Special Access Scheme (SAS) provides patient access to cannabis on compassionate grounds without the usual quality and safety data requirements.
This means approval is granted on a case-by-case basis provided the correct documentation is given by the prescribing doctor, says Dr. John Lawson, a pediatric neurologist and conjoint senior lecturer at the University of New South Wales.
A recent trial published in The New England Journal of Medicine, led by Australian neurologist Professor Ingrid Scheffer, found cannabidiol – one of at least 113 compounds found in the cannabis plant – significantly reduced the severity and frequency of seizures in children with a rare, yet devastating form of epilepsy known as a Dravet syndrome.
Last year, the Medical Cannabis Council called for more robust research to be done to ensure patients greater access in the future.
Read the full article in The Guardian
In essence, San Francisco is resetting the clock on the War on Drugs, at least for cannabis. The city is expanding upon Proposition 64, the state law that went into effect this year that makes amnesty for weed-related crimes a condition for legalizing cannabis in California.
As incredibly progressive as that ordinance is, San Francisco is not alone in attempting to work racial equity into the new legalized cannabis landscape. Cities across California and other states are upping the racial equity quotient in various ways, in what looks like a race to the top for seeking true racially and economically inclusive outcomes. As city leaders scratch their heads over how to realize real racial equity in policymaking, the legalized weed experiment is acting as the test case and is already proving itself sticky enough that cities are almost competing to be the most weedfully woke.
It’s not just the historically uber-liberal Bay Area that’s embarking on this. Los Angeles also has a cannabis social equity program that prioritizes business permits for people with low incomes, who have lived in an area ravaged by the drug war, have criminal records (because of past weed prohibition), and who plan to hire at least half of their workforces from local residents. Both Oakland and L.A. are also prioritizing permits for people who don’t personally fall under this criteria but are willing to finance or lease space to applicants who do.
Despite the heavy regulation of the cannabis market at both the city and state level (and maybe the federal level if Senator Cory Booker has it his way), there has still been immense growth in revenue and profits in this field. According to the 2017 Cannabis Industry Annual Report, from New Frontier Data, “The legal cannabis market was worth an estimated $6.6 billion in 2016, and annual sales are projected to grow at a compound annual growth rate (CAGR) of 16% to reach more than $24 billion by 2025.” And that’s only based on the states where weed is currently legal.
Read the full article at CityLab
Spoiler alert for those attending the Winter Fancy Food Show today through Tuesday in San Francisco: There are no cannabis edibles on the trade-show floor. Cannabis cuisine is not the subject of any plenary panel.
In November, the Fancy Food Show’s parent, the Specialty Food Association (SPA), ranked cannabis number eight of the top-10 food trends to watch in 2018.
“As more states legalize recreational marijuana, the varieties of pot-enhanced food and beverage will increase,” the SPA’s Trendspotter Panel wrote last November. “Look out for continued interest and acceptance in a host of snacks, treats and beverages with a little something extra.”
Nielsen is vice president of trends and marketing at CCD Innovation, an Emeryville food, and beverage development agency. She’s attending the Fancy Food Show today through Tuesday at Moscone Center. As a member of the Specialty Food Association’s Trendspotters — an expert panel comprised of marketers, journalists, and other tastemakers — she’ll roam the Fancy Food Show trade-show floor looking for new and innovative products. There are no cannabis edibles at this year’s Fancy Food Show, but the SPA’s Trendspotters won’t have to go far to find them.
There are five retail cannabis stores reachable via short walk, taxi or rideshare. And many of the edibles on sale in these stores look like they might have sneaked over from the show.
Read more at GreenState
California has now joined a number of states changing their approach to marijuana, which marks exciting times for national drug reform. If you’re over the age of 21, it is now legal to grow up to six plants and possess up to an ounce (!) on your person.
While the state’s residents have already been celebrating the news, tracking down a spot to purchase your recreational weed may prove a little difficult in these early days.
However, this may not indicate the end of drug dealers pedaling marijuana, as taxes are expected to raise the retail cost of the pot up to 70 percent higher than the street price. Nonetheless, It’s a very, very happy new year for Californians.
Mike Tyson has been a boxer, an actor, a monologuist, and an animated detective, but now it looks like the former heavyweight champion wants to take a bite out of California’s new legal weed game.
According to the Blast, Tyson and two business partners—Robert Hickman and Jay Strommen—have plans to build a massive “cannabis resort” on 40 acres of desert land in California City. The trio broke ground on the property back in December and are getting things rolling now that California has officially legalized marijuana.
It seems like the rest of the Mojave Desert land, though, will earn Tyson Ranch its “resort” title. The Beast reports that there will be “premium ‘glamping’ campgrounds and cabins” for people to stay in, an amphitheater for live music, and a factory for marijuana edibles.
The resort’s land isn’t far from Edwards Air Force Base, and the Blast reports that the ranch will be staffed mostly by veterans and will be committed to helping those in the armed forces, as CBD, a marijuana compound that won’t get you high, has been used to treat PTSD.
Read more at Vice